Cargando…
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer
Cyclooxygenase-2 (COX-2) and its primary enzymatic product, prostaglandin E2 (PGE2), are associated with a poor prognosis in breast cancer. In order to elucidate the factors contributing to intratumoral PGE(2) levels, we evaluated the expression of COX-2/PGE(2) pathway members MRP4, the prostaglandi...
Autores principales: | Kochel, Tyler J, Reader, Jocelyn C, Ma, Xinrong, Kundu, Namita, Fulton, Amy M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351651/ https://www.ncbi.nlm.nih.gov/pubmed/28029661 http://dx.doi.org/10.18632/oncotarget.14145 |
Ejemplares similares
-
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE(2)-mediated immunosuppression and inhibits breast cancer metastasis
por: Ma, Xinrong, et al.
Publicado: (2013) -
Upregulation of Cyclooxygenase-2/Prostaglandin E(2) (COX-2/PGE(2)) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer
por: Kochel, Tyler J., et al.
Publicado: (2016) -
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
por: Kundu, Namita, et al.
Publicado: (2013) -
The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem
Cells
por: Kundu, Namita, et al.
Publicado: (2019) -
Eicosanoids in Cancer: Prostaglandin E(2) Receptor 4 in Cancer Therapeutics and Immunotherapy
por: Ching, Mc Millan, et al.
Publicado: (2020)